Welcome to our dedicated page for Baxter Intl news (Ticker: BAX), a resource for investors and traders seeking the latest updates and insights on Baxter Intl stock.
Baxter International Inc (NYSE: BAX) is a global healthcare leader specializing in life-saving renal care, advanced medical devices, and hospital solutions. This page provides investors and healthcare professionals with timely updates on the company’s operational developments, regulatory milestones, and strategic initiatives.
Access authoritative information about Baxter’s latest financial results, product innovations, and partnerships. Our curated news collection simplifies tracking of critical updates across key areas including dialysis technologies, infusion systems, and biosurgery products.
Discover official announcements regarding:
• Quarterly earnings and financial guidance
• New product approvals and clinical trials
• Strategic acquisitions in medical technology
• Regulatory compliance updates
• Leadership changes and corporate governance
Bookmark this page for streamlined access to Baxter’s verified news developments. Check regularly for updates that may impact market positioning and healthcare sector trends.
Baxter International Inc. (NYSE:BAX) has received FDA approval for an expanded indication for Clinolipid (Lipid Injectable Emulsion) for pediatric patients, including preterm and term neonates. Clinolipid provides essential fatty acids and calories for parenteral nutrition when oral or enteral nutrition is not possible. The approval highlights Baxter's commitment to meeting the nutritional needs of patients of all ages.
Baxter International Inc. (NYSE:BAX) will present at the Bank of America 2024 Health Care Conference with its chief financial officer, Joel Grade, scheduled to speak on May 15, 2024. The live webcast will be available for replay until August 14, 2024. Baxter is a global medtech leader offering a variety of healthcare products and solutions across the world.
Baxter International Inc. (NYSE:BAX) has declared a quarterly cash dividend of $0.29 per share of common stock, with an indicated annual dividend rate of $1.16 per share. The dividend will be payable on July 1, 2024, to stockholders of record as of May 31, 2024.
Baxter International Inc. reported first-quarter 2024 results with sales of $3.59 billion, up 2% on a reported basis and 3% on a constant currency basis, surpassing guidance. U.S. GAAP EPS was $0.07, adjusted EPS was $0.65. Full-year sales growth outlook is 2% (reported) and 2-3% (constant currency). Recent FDA clearance of Novum IQ large volume infusion pump and Dose IQ Safety Software. Baxter is focused on operational execution, innovation, and value creation for stakeholders.
FAQ
What is the current stock price of Baxter Intl (BAX)?
What is the market cap of Baxter Intl (BAX)?
